We’ve entered a new era. One where being risk averse is the riskiest strategy, long-established operating models have been torn up and reimagined, and where investment into digital innovation – both culturally and financially – has ignited.
Your challenge now? Scale, widen and hone this transformational potential or fall behind rapidly evolving customer and patient need. Digital must be embedded into every facet of your organisation; enterprise data infrastructure, AI and advanced analytics must dictate each stakeholder interaction; and “patient centricity” must become obsolete – so ingrained into your organisation’s every action that it is subconscious.
Join thousands of your peers at the world’s gathering for pharma pioneers and health innovators – Reuters Events Pharma 2021 (formerly eyeforpharma Barcelona) – the biggest, most senior and cross-functional commercial pharma event.
We may be in the year of the vaccine, but we’re just beginning the decade of pharma’s awakening.
The Eminent Speakers:
This year’s industry defining themes:
-
Reimagine digital engagement possibilities:Deliver personalised HCP and patient experiences by assembling hybrid field teams and executing on omnichannel through rep and MSL orchestrators. Implement an integrated Go-To-Market strategy fit for both virtual and face-to-face environments.
-
Collaboration as your competitive advantage:Optimise new pre-competitive opportunities with industry partners, foster long-term patient group and healthcare partnerships to catalyse patient value, and finally destroy internal silos to empower agile and innovative strategies.
-
Data-centricity:Rebuild commercial and medical data-foundations with a unified infrastructure, deploy and scale fit-for-your-purpose predictive analytics, and generate actionable insights on real-world customer behaviours and profiles to better inform decision-making.
-
Lead the health innovation revolution:Expand access to novel treatments, such as C>, with new external collaborative networks that enable early, flexible and sustained stakeholder dialogue; design patient focused value-added services to satisfy new regulatory needs; and mature RWE and patient insight capabilities to enable outcomes-driven access at scale.
